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Purpose: We studied the gene copy number alteration of TPPP (Tubulin
Polymerization Promoting Protein) in bladder cancer using ﬂuorescence in
situ hybridization (FISH) based assay and correlated it's the result with
clinical parameters.
Materials and Methods: Samples and clinical data from patients with
bladder cancer and clinical data were collected. TPPP gene was evaluated
by FISH in 52 patients. The probe targeting the gene TPPPwere established
for FISH experiment. At least 300 non-overlapping cells in each case were
analyzed by two observers.
Results:We could see different genetic copy number alterations of TPPP in
studied sample. Further analysis with the clinical data, the TPPP gene
alteration was strongly correlated with tumor grade, in which the ampli-
ﬁcation of TPPP gene was signiﬁcantly correlated with high-grade tumor
(p< 0.001). Besides, the ampliﬁcation of TPPP gene was positively corre-
lated with tumor stage (p< 0.05).
Conclusion: The genetic alterations of TPPP gene were much higher in
high-stage and -grade bladder cancer. This result suggests that TPPP may
play a role in bladder cancer pathogenesis, and TPPP gene alteration may
serve as a biomarker for bladder cancer detection.
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Purpose: We evaluated the clinical outcomes of castration resistant
prostate cancer (CRPC) patients treated with Docetaxel in Taichung Vet-
erans General Hospital.
Materials and Methods: From Dec 2004 to Feb 2015, 208 patients with
castration resistant prostate cancer were treated with Docetaxel70-75mg/
m2, IV, every three to four weeks or 50mg/m2, every two weeks. The PSA
response, time to progression duration, overall survival and adverse events
wereanalyzed.
Results: The median age of the 208 patients was 69 years (range 44e86)
and the median PSA when started Docetaxel was 47 ng/ml (range
2.24e4761). The median treatment courses of the patients were 6 (range
1e44). PSA response was found in 105patients (50.5%). Twenty-eight pa-
tients (13.5%) had the phenomenon of PSA ﬂare up. The median progres-
sion free survival was 5 months (range 0e54) and the median overall
survival was 13 months (range 0e80). The most common subjective
adverse effects were neutropenia. About one-third patients (35%) had
grade3e4 neutropenia
Conclusion: Good PSA response and fair survival outcome were demon-
strated in CRPC patients treated with docetaxel. However, high risk of
neutropenia should be kept in mind.
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Purpose: Chloroquine (CQ) widely used to treat and prevent malaria, is
shown to be an important therapeutic compound to treat diseases such as# These authors contributed equally to this work.autoimmune disorders. Recently, CQ is also recognized as a potent adju-
vant agent when combined with other chemotherapeutic drugs to treat
cancers. However, the effects of a single treatment of CQ on bladder cancer
(BC) have not been investigated. In the present study, we aimed to examine
the cell death mechanism induced by CQ in BC cells.
Materials and Methods: The effect of CQ on the growth and viability of BC
cells (5637 and T24) in vitro was examined by cologenic formation assay
and WST-1 reagent, respectively. The morphology and numbers of lyso-
somes in live cells with or without CQ treatment was tracked using a
ﬂuorescent dye, LysoTracker. The induction of lysosomal membrane
permeability (LMP) was detected by acridine orange translocation, and
further investigated by the immunoﬂuorescent detection of cathepsin B
and D (CatB and CatD) release. The expression level of bid, caspase-3, and
cytosolic cytochrome c in CQ-treated cells was detected by Western blot.
Lysosomal protease inhibitors, pepstatin A and E64d were used to atten-
uate CQ-induced LMP.
Results: CQ exhibited cytotoxicity toward human bladder cancer cell lines.
Time-lapse monitoring of lysosomes labeled with LysoTracker showed
diminishing of ﬂuorescent in CQ-treated cells, suggesting that CQ targets
lysosomal functions. This was further supported by dose-dependent AO
translocation detected with increased concentration of CQ, and the
releasing of CatB and CatD into cytosol. The increased level of cleavage bid
and cytosolic cytochrome c indicated mitochondrial outer membrane
permeabilization (MOMP), and subsequently leading to apoptosis induc-
tion judged by the increased level of cleaved caspase 3. Furthermore, the
reduced cell viability, the release of CatB and CatD, the level of cytosolic
cytochrome c and cleaved caspase3 were attenuated by the pretreatment
of pepstatinA/E64 which are inhibitors of lysosomal protease suggesting
CQ induced LMP is responsible for CQ-induced apoptotic cell death in
human BC cells.
Conclusion: CQ exhibits cytotoxicity in human bladder cancer cells by
enhancing LMP that ampliﬁes apoptotic signaling and ultimately leading
to cell death.
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Purpose: Robotic partial nephrectomy is an increasingly performed,
minimally invasive alternative to open partial nephrectomy. We compared
early postoperative outcomes in 102 patients undergoing robotic and open
partial nephrectomy.
Materials and Methods: Data on 102 consecutive robotic or open partial
nephrectomies were collected retrospectively from 2008 to 2014 in our
centers. Demographic, intraoperative, postoperative and followup data
were compared between the 2 groups.
Results: Between the robotic (n¼ 59) and open (n¼ 43) partial nephrec-
tomy groups signiﬁcant differences were noted in ischemic time (31.86 vs
46.70minutes, p< 0.001), and preoperative glomerular ﬁltration rate (92.8
vs 78.2 ml/minute/1.73 m2, P¼ 0.004). Sex, surgical margin, blood loss,
mean hospitalization days, complication rate, postoperative blood trans-
fusion rate, recurrent rate andmortality rate were similar between the two
groups. Preoperative glomerular ﬁltration rate is the only risk factor of
postoperative glomerular ﬁltration rate declined at one year (p¼ 0.005).
Patients in the robotic group with preoperative GFR< 74.49 ml/minute/
1.73 m2 and open group preoperative GFR< 57.06 with ml/minute/1.73m2
were far more likely (p< 0.001) to have an estimated glomerular ﬁltration
rate less than 45 ml/minute/1.73 m2 after postoperative one year follow-
up.
Conclusion: Our results suggest that preoperative GFR was the most ac-
curate predictor of actual postoperative renal function at one year.
Although ischemia type and ischemia time were not associated with renal
function at postoperative one year, open partial nephrectomy is more
favorable than robotic partial nephrectomy in terms of patient with worse
preoperative renal function.
